FDA Gives Green Signal To Annovis Bio's Parkinson's Trial With Buntanetap

Annovis Bio Inc  (NYSE: ANVS ) received notice  from the FDA that the Phase 3 clinical study with buntanetap in early Parkinson's patients may proceed.  The FDA accepted the final protocol and the clinical development plan and approved using the company's new large-scale batch of good manufacturing practice material. The agency found the chronic toxicology in rats and dogs safe and adequate ... Full story available on Benzinga.com